TGTXTG Therapeutics, Inc.
The Read
TG Therapeutics’ stock showed little reaction to a Q4 2025 earnings miss offset by strong Briumvi sales growth and robust 2026 guidance, then remained flat after Q1 2026 results met EPS estimates with steady commercial performance.
The schedule
- Thu15Oct
Potential secondary offering could impact the stock price, with potential dilution or increased capital for growth.
- Wed4Nov
Earnings report and guidance for Q3 2026, with potential updates on clinical trials and pipeline progress.
- Tue9Feb
Earnings report and guidance for Q4 2026, with potential updates on clinical trials and pipeline progress.
- Wed5May
Earnings report and guidance for Q1 2027, with potential updates on clinical trials and pipeline progress.
- Fri6Aug
Earnings report and guidance for Q2 2027, with potential updates on clinical trials and pipeline progress.
Past
- Wed5Aug
Actual outcome: Bear · $49.16 at outcome
TGTX missed Q2 earnings estimates, reporting an EPS of $0.0549 versus the expected $0.0549, which was a 0.0% beat. However, the stock fell materially to $49.16, below the bear floor of $49.50, driven by mixed guidance and concerns over U.S. MS uptake and SG&A pressures, despite a revenue surge from Briumvi.
Q2 2026 earnings on 2026-08-07 will focus on whether Briumvi revenue growth and margins stay on the current profitable trajectory. A clean beat on the company’s $825M–$850M 2026 revenue framework with stable MS market share could push TGTX toward $58.50, while any slowdown in U.S. uptake, pricing pushback, or higher-than-expected SG&A could drive the stock down toward $58.50 by 2026-08-12.
- Wed6May
Actual outcome: Bull · $43.03 at outcome
TG Therapeutics reported Q1 2026 EPS of $0.16, exactly matching Wall Street estimates. With results perfectly in line with expectations and no major surprises regarding Briumvi's commercial trajectory, the stock remained flat at $36.10, sitting squarely between the bull and bear targets.
TG Therapeutics reported Q1 2026 EPS of $0.16, exactly matching Wall Street estimates. With results perfectly in line with expectations and no major surprises regarding Briumvi's commercial trajectory, the stock remained flat at $36.10, sitting squarely between the bull and bear targets.
- Fri27Feb
Actual outcome: Mixed · $29.27 at outcome
TG Therapeutics reported a significant Q4 earnings miss of $0.14 per share against the $0.35 estimate, but this was balanced by 90% year-over-year growth in Briumvi sales and robust 2026 revenue guidance of $825M–$850M. The stock remained flat as the market weighed the bottom-line shortfall against strong commercial adoption and the achievement of a clinical milestone for Azer-cel in multiple sclerosis.
TG Therapeutics reported a significant Q4 earnings miss of $0.14 per share against the $0.35 estimate, but this was balanced by 90% year-over-year growth in Briumvi sales and robust 2026 revenue guidance of $825M–$850M. The stock remained flat as the market weighed the bottom-line shortfall against strong commercial adoption and the achievement of a clinical milestone for Azer-cel in multiple sclerosis.